Over the past several decades, China has experienced substantial improvements in life expectancy (LE), signifying major advancements in public health outcomes.

This study offers an in-depth analysis of the contributions made by various diseases and age demographics to the growth of LE in China over the past 35 years, highlighting crucial factors that influence population health.

The results highlight the need for interventions tailored to various disease types and age groups in order to enhance LE and improve public health outcomes. Public health strategies should prioritize disease prevention, control initiatives, and enhancements in healthcare services that are specifically designed to meet the needs of distinct population demographics.

Infertility represents a significant global public health concern, impacting approximately 15% of couples of reproductive age worldwide. Despite this, data on infertility prevalence in the demographically diverse Asia-Pacific region remains sparse.

This study examines the trends and distribution of infertility in the Asia-Pacific region from 1990 to 2021, revealing a significant increase in female infertility. The growth rate of secondary infertility has exceeded that of primary infertility. Additionally, an increase in the prevalence of polycystic ovary syndrome (PCOS) may be a significant contributor. The research also highlights geographical variations in the prevalence and trends of infertility across different countries.

The findings emphasize the significance of sexual and reproductive health services and rights in safeguarding fertility.

Chronic disease multimorbidity is prevalent among older Chinese people, seriously affecting their well-being and quality of life.

This study estimated the impact of multimorbidity on the risk of health state transitions and health expectancy among older adults in China. It used population-representative, long-term longitudinal data and multi-state Markov modeling along with microsimulation methods.

The study results suggest that the Chinese government should strengthen the prevention and management of multimorbidity and accelerate the transition from chronic disease management to multimorbidity management.